Can immune markers predict success of alternative chemoradiotherapy in head and neck cancer?
NCT ID NCT06947668
First seen Mar 17, 2026 · Last updated May 24, 2026 · Updated 13 times
Summary
This study looks at immune markers in tumor tissue, saliva, stool, and blood from 250 patients with head and neck cancers who cannot receive the standard chemotherapy drug cisplatin. Instead, they will receive chemoradiotherapy with docetaxel. The goal is to find out which immune features predict treatment success, survival, and side effects, helping doctors choose better treatments for these patients in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARYNX SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Universitätsklinikum Erlangen, Strahlenklinik
RECRUITINGErlangen, Bavaria, 91054, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.